HPS masthead
What's New?
. Fukushima Decontamination Report
. CRCPD & CDC Grants for Volunteer Corps
. America's Nuclear Future
. February Newsletter
. Boice Nominated President of NCRP
. February Journal
. February ORS
. Schauer Given the Butterfly Award from Image Gently
. Kase President's Report to IRPA
. IRPA13 Accepting Posters
Upcoming Events
. HPS Midyear - Issues in Waste Management
5-8 February 2012
Dallas, Texas
. NRC Regulatory Information Conference
NRC Regulatory Information Conference
13-15 March 2012
Rockville, Maryland
. NCRP Annual Meeting
12-13 March 2012
Washington, DC
. James E. Turner Memorial Symposium
Call for Abstracts
18-19 April 2012
Oak Ridge Associated Universities, Pollard Auditorium, Oak Ridge, Tennessee
. IRPA13
13-18 May 2012
Glasgow, Scotland
. Canadian Radiation Protection Association (CRPA) Annual Meeting
27-30 May 2012
Halifax, Nova Scotia
. ACS Undergrad Summer Schools
10 June- 20 July 2012
. Nuclear Regulatory Commission Meeting Webcasts
February 2012
Bethesda, Maryland
09 February 2012

Answer to Question #1527 Submitted to "Ask the Experts"

Category: Nuclear Medicine Patient Issues — Therapeutic Nuclear Medicine

The following question was answered by an expert in the appropriate field:

Q
What is the tolerance dose to normal liver from 131I-labelled agents used for radionuclide therapy, in particular 131I lipiodol? How does it compare to the values used by radiation oncologists for fractionated external beam therapy?
A
That's an interesting question, but we don't have an answer to it because (1) the absorbed dose is probably nonuniform, with certain cells being "overkilled" by the beta radiation, and others not killed at all, (2) we are, to my knowledge, lacking a data base of patients whose livers have been destroyed by radionuclide therapy, and (3) the answer will vary depending upon whether the liver is normal, aged, diseased, or injured by prior chemicals, including drugs. I would expect that physicians would administer such a radiopharmaceutical, watch liver enzymes, and then stop when tolerance appeared to be reached. I would assume that patients getting such treatment already have a potentially fatal disease. One needs to treat to a tolerance dose because undertreatment will be useless. It would depend upon the case, but I expect there would be at least some monitoring of liver function to try to avoid fatal toxicity, but it is necessary to realize that toxicity is often reversible, and in the pediatric population is amazingly reversible, so that even the occurrence of toxicity is not necessarily a reason to stop a therapy that has some chance of success. From a practical point of view, I would expect that the radiation exposure range at which one can reach tolerance will be greater than that for external beam radiation of 1,500-2,000 rad for a single treatment dose and a total of 3,500-4,000 rad for fractionated doses. It would therefore be reasonable clinically to do liver function tests beginning about at the external beam tolerance dose, or perhaps lower if the liver is aged, diseased, or previously exposed to toxic chemicals or radiation. I hope this helps.

Carol S. Marcus, PhD, MD, ABNM
Professor of Radiological Sciences and of Radiation Oncology, UCLA
Answer posted on 11 January 2002. The information and material posted on this website is intended as general reference information only. Specific facts and circumstances may alter the concepts and applications of materials and information described herein. The information provided is not a substitute for professional advice and should not be relied upon in the absence of such professional advice specific to whatever facts and circumstances are presented in any given situation. Answers are correct at the time they are posted on the Website. Be advised that over time, some requirements could change, new data could be made available, or Internet links could change. For answers that have been posted for several months or longer, please check the current status of the posted information prior to using the responses for specific applications.
image
image
Home Affiliates Ask the Experts Radiation Terms Employment Meetings